Major Funding Rounds Across Biotech, AI Agents and Humanoid Robotics in August 2026
In August 2026, eight biotech firms, an AI‑agent startup and several robotics companies secured multi‑hundred‑million‑dollar rounds to advance therapies, AI services and humanoid robot production.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Robotics
XPeng’s robotics division raised more than $900 million in a financing round announced 29 August 2026, valuing the unit at over $6.3 billion. The round was led by IDG Capital and included Gaorong Ventures, Tencent and Alibaba; founders He Xiaopeng and co‑president Brian Gu each contributed roughly $100 million of personal capital. The capital will fund mass production of the humanoid robot IRON, slated for launch by the end of 2026, and underpin XPeng’s broader embodied‑AI strategy. The funding represents the largest single round in China’s embodied‑AI sector, though XPeng’s share price showed little movement, reflecting investor focus on the company’s core EV business. [1][3]
Wonik Robotics announced a growth‑equity round of 350 billion KRW (≈$253 million) on 27 August 2026 to build mass‑production facilities for humanoid robots and robot hands. The National Growth Fund led with a 150 billion KRW convertible preferred investment, while private investors contributed the remaining 200 billion KRW. Wonik, known for its Allegro Hand supplied to Nvidia and Meta, will use the funds to construct a robot‑hand production plant and an AI transformation centre in Wanju, North Jeolla, and to develop core components in‑house, addressing the actuator and hand cost bottleneck in humanoid hardware. The investment is part of South Korea’s “M.AX Frontier Project” to boost physical AI capacity. [2]